Sionna Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SION | RNTX | ARCT | CTNM | ATYR | RNA | |
|---|---|---|---|---|---|---|
| Market cap | 168.41M | 56.82M | 308.96M | 368.31M | 15.45M | 148.48M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.7 | — | -2.9 | -5.0 | -0.3 | -1.5 |
| Price/book | 0.6 | 5.5 | 1.8 | 1.4 | 0.3 | 0.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −89.60% | −57.99% | +10.42% | −7.18% | −79.64% | −41.15% |
| Today | +2.19% | −1.32% | +13.94% | +1.03% | −6.79% | −0.46% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SION news ›A carbon-silica bond with benefits — safe drug delivery to lungs
For years, medical science has been confronting a frustrating paradox: Microscopic silica particles are great at carrying drugs straight to diseased lungs, but they also leave behind a toxic trail. A team at the Indian Institute of…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION). Such... NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on…
DGFT Notifies Four New SIONs for Doxycycline and Clobetasol Exports
Government of India Ministry of Commerce & Industry Department of Commerce Directorate General of Foreign Trade Subject: Fixation of four new Standard Input-Output Norms (SIONs) at SION Nos. A-3715, A-3716, A-3717 & A-3718 under “Chemical…
Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic
Investing News Network Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic - Lidia Pieri to serve as Chief Op
Press Release: Lou Correa Introduces Bill to Prevent and Treat Silicosis
Correa and Dexter propose federal grants for silicosis education, screening, treatment, and worker protection. Bill introduced to address silicosis: Reps. Lou Correa of California and Maxine Dexter of Oregon say they have introduced the…
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1 stabilizers in combination with other…
Analysts’ Opinions Are Mixed on These NA Stocks: HealthStream (HSTM), Inter Parfums (IPAR) and Sionna Therapeutics, Inc. (SION)
Analysts have been eager to weigh in on the NA sector with new ratings on HealthStream (HSTM), Inter Parfums (IPAR) and Sionna Therapeutics, Inc. (SION). Canaccord Genuity analyst Richard Close maintained a Hold rating on HealthStream…
LifeSci Capital Sticks to Its Hold Rating for Sionna Therapeutics, Inc. (SION)
LifeSci Capital analyst Gaurav Maini maintained a Hold rating on Sionna Therapeutics, Inc. today and set a price target of $6.00. Maini covers the Healthcare sector, focusing on stocks such as Tenax Therapeutics, Liquidia Technologies, and…
Sionna Advances SION-451/SION-2222 Combo Based on SION-719 Analysis
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Sionna Advances SION-451/SION-2222 Combo Based on SION-719…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com7
- defenseworld.net1
- investingnews.com1
- prnewswire.com1
- taxguru.in1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.